Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Last trade$7.25
Day change-$0.425 (-5.54%)
Day range$7.05 – $8.17
Volume2,364,283
Market cap$612M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for HELP.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for HELP.
Recent news
Company coverage with links to the original publishers.
Helus Pharma announced it will present topline results from its Phase 3 APPROACH study evaluating HLP003 for major depressive disorder on November 16, 2026. HLP003, a novel serotonergic agonist, has received FDA Breakthrough Therapy Designation. The company is also developing HLP004 for generalized anxiety disorder in Phase 2 trials.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.